Applied Clinical Trials
Survey collects thoughts from industry professionals on the current and future impact of big data in clinical trials.
In October, SCORR Marketing and Applied Clinical Trials surveyed our audience on big data. As results indicate at right, most respondents agree that big data is important to the clinical research enterprise. However, when asked if it was important in their own companies, those numbers were noticeably higher in the “slightly” to “not at all” categories.
Regardless, the survey did uncover some big data trends. For example, the majority of respondents are using medical records, biomarker and registry data as sources, in that order. Of those, the medical record data is rated the most important by 48% of the respondents.
As for the future uses and impact of big data in clinical trials, some areas are brighter than others. One-third of respondents believe the EHR will be the data of record for all new patient data, and an additional one-fourth believe that predictive modeling will be used to inform preclinical and translational research.
Conversely, only 4% of respondents think patient recruitment rates will be improved in five years if they used big data. Please download the free report here.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.